Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 510 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Dysfunction Clear all
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 25, 2026, 4:34 AM EDT
Completed No phase listed Observational

Diffuse Myocardial Fibrosis in Fontan Patients

NCT01929174
View directory record Official record
Conditions
Congenital Heart Disease, Single Ventricle, Myocardial Fibrosis
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease

NCT03508609
View directory record Official record
Conditions
Coronary Microvascular Dysfunction
Interventions
CLBS16
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 25, 2026, 4:34 AM EDT
Withdrawn Phase 1 Interventional

REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts

NCT01496209
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Chronic Ischemic Cardiomyopathy
Interventions
Endomyocardial injections of allogeneic Human CSps, Endomyocardial injections of vehicle only.
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Oct 25, 2026, 4:34 AM EDT
Suspended Phase 3 Interventional

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial

NCT06566183
View directory record Official record
Conditions
Coronary Artery Disease, Cognitive Impairment, Heart Failure
Interventions
Guideline-directed medical therapy (GDMT), Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI).
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

NCT03934905
View directory record Official record
Conditions
Anthracycline Related Cardiotoxicity in Breast Cancer
Interventions
sulforaphane, Placebo Oral Tablet
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Enrolling by invitation Not applicable Interventional

Coronary Sinus Reducer For The Management Of Symptomatic Heart Failure

NCT07057323
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction
Interventions
Coronary Sinus Reducer
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Recruiting Not applicable Interventional

Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

NCT04555161
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
Interventions
Aria CV Pulmonary Hypertension System
Device
Lead sponsor
Aria CV, Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 25, 2026, 4:34 AM EDT
Completed No phase listed Observational

Classification of Heart Failure With Preserved Ejection Fraction

NCT01030991
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Diastolic Heart Failure
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 25, 2026, 4:34 AM EDT
Withdrawn Not applicable Interventional

Partial Heart Transplantation

NCT06055556
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Partial Heart Transplantation, Freshly procured valve
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
Up to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 25, 2026, 4:34 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

NCT04449198
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Resveratrol, Placebo
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Early Detection of Diastolic Dysfunction and the Role of Lifestyle Measures in Its Treatment

NCT00998114
View directory record Official record
Conditions
Diastolic Dysfunction
Interventions
Exercise
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 25, 2026, 4:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

To Evaluate if Wide Blood Sugar Fluctuations Lead to Injury of Heart Function and Heart Nerves

NCT01170832
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 25, 2026, 4:34 AM EDT
Not yet recruiting Not applicable Interventional

A Plant-Based Diet in the Treatment of Coronary Microvascular Dysfunction

NCT07821372
View directory record Official record
Conditions
Coronary Microvascular Dysfunction
Interventions
Polyphenol-Rich Plant-Based Diet
Other
Lead sponsor
Emory University
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Active, not recruiting No phase listed Observational

COMPASSION S3 Post-Approval Study

NCT04860765
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction
Interventions
SAPIEN 3 THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Active, not recruiting Not applicable Interventional

Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women

NCT05534932
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Remote Patient Monitoring
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 25, 2026, 4:34 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 18 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of P-188 NF in DMD Patients

NCT03558958
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
P-188 NF
Drug
Lead sponsor
Phrixus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 25 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 25, 2026, 4:34 AM EDT
Recruiting No phase listed Observational

Registry of Patients With Takotsubo Syndrome

NCT03663348
View directory record Official record
Conditions
Takotsubo Cardiomyopathy, Broken Heart Syndrome, Tako-tsubo Cardiomyopathy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 110 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Nitric Oxide, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 25, 2026, 4:34 AM EDT
Terminated Phase 4 Interventional Results available

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

NCT03249272
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 25, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Cardiac Sympathetic Activity in Patients With the Apical Ballooning Syndrome

NCT00586183
View directory record Official record
Conditions
Apical Ballooning Syndrome
Interventions
PET scan
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 25, 2026, 4:34 AM EDT
Completed No phase listed Observational

Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation

NCT02428894
View directory record Official record
Conditions
Ventricular Dysfunction, Left
Interventions
LVAD
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 25, 2026, 4:34 AM EDT